Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

ABSTRACT: We report the transcriptomics of squamous lung cancer patient derived tumoroids treated with EZH2 inhibitor and IFNy

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE233468 | GEO | 2023/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

Project description:We report the chromatin landscape of squamous lung cancer patient derived tumoroids treated with EZH2 inhibitor and IFNy

2023-05-31 | GSE233469 | GEO

EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

Project description:We report the transcriptomics of primary murine lung squamous cell carcinomas in mice treated with EZH2 inhibition and anti-PD1

2023-06-01 | GSE233665 | GEO

EZH2 inhibtion and IFNy treatment of patient derived organoids

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids

| PRJNA976305 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]

| PRJNA977552 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq]

| PRJNA976310 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

Project description:EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq]

| PRJNA976311 | ENA

EZH2 inhibtion and IFNy treatment of patient derived organoids

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-05-31 | GSE233470 | GEO

Affinify Purification of EZH2 and phosphodeficient EZH2 identifies phosphorylation dependent interactions of EZH2

Project description:Overexpression of EZH2 in estrogen receptor negative (ER-) breast cancer promotes metastasis. EZH2 has been mainly studied as the catalytic component of the Polycomb Repressive Complex 2 (PRC2) that mediates gene repression by trimethylating histone H3 at lysine 27 (H3K27me3). However, how EZH2 drives metastasis despite the low H3K27me3 levels observed in ER- breast cancer is unknown. We have shown that in human invasive carcinomas and distant metastases, cytoplasmic EZH2 phosphorylated at T367 is significantly associated with ER- disease and low H3K27me3 levels. Here, we explore the interactome of EZH2 and of a phosphodeficient mutant EZH2_T367A. We identified novel interactors of EZH2, and identified interactions that are dependent on the phosphorylation and cellular localization of EZH2 that may play a role in EZH2 dependent metastatic progression.

2018-07-03 | PXD010073 | Pride

Full proteome analysis of WT and Ezh2-KO K562 cells

Project description:Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms that lead to resistance development remain to be defined in detail. Here we report that loss-of-function mutations (LOF) in the histone methyltransferase EZH2 have the potential to confer resistance against the chemotherapeutic agent cytarabine. We identify seven distinct EZH2 mutations leading to loss of H3K27 trimethylation via multiple mechanisms. Analysis of matched diagnosis and relapse samples reveal a heterogenous regulation of EZH2 and a loss of EZH2 in 50% of patients. We confirm that loss of EZH2 induces resistance against cytarabine in the cell lines HEK293T and K562 as well as in a patient-derived xenograft (PDX) model. Proteomics and transcriptomics analysis reveal that resistance is conferred by upregulation of multiple direct and indirect EZH2 target genes that are involved in apoptosis evasion, augmentation of proliferation and alteration of transmembrane transporter function. Our data indicates, that loss of EZH2 results in upregulation of its target genes, providing the cell with a selective growth advantage, which mediates chemotherapy resistance.

2021-03-12 | PXD023139 | Pride

Ezh2 WT, Het, and Null Mouse Organoid Transcriptome

Project description:We report the transcriptomics of Ezh2-/-, Ezh2+/-, and Ezh2+/+ mouse organoids

2022-06-30 | GSE184347 | GEO